文献速递心外重症与机械循环支持

基线肾功能受损可能不影响左心室辅助装置植入后的结局与生存

Impaired Baseline Renal Function May Not Influence Outcomes and Survival After Left Ventricular Assist Device Implantation.
PubMed 文献 · Ann Thorac Surg · 2020-07-19

该回顾性研究纳入255例左心室辅助装置(LVAD)植入患者,按术前估算肾小球滤过率(eGFR)分为>60与<60 mL/min/1.73 m2两组及6个肾功能分级。结果显示,术前eGFR<60组术后1个月eGFR显著升高(P<.001),且4年时仍显著高于基线(P=.032);两组1、3、5年生存率无显著差异(P=.92)。结论认为术前肾功能不全不影响LVAD长期结局与生存。

要点

  • LVAD植入后1个月整体eGFR从75.19升至118.97 mL/min/1.73 m2(P<.001)。
  • 术前eGFR<60组术后1个月显著升高,4年时仍高于基线(P=.032)。
  • 术前eGFR>60与<60组1、3、5年生存率无显著差异(P=.92)。

核心结论

  • 术前eGFR低的患者可从LVAD治疗中获益,eGFR持续高于术前水平。
  • 术前肾功能不全未对长期发病率与死亡率产生负面影响。

研究设计与样本

  • 回顾性分析255例LVAD植入患者,按术前eGFR<60或>60 mL/min/1.73 m2分为2组,并分为6个肾功能分级。

主要发现

  • 术后1个月总队列eGFR从基线75.19 ± 34.35升至118.97 ± 67.62 mL/min/1.73 m2(P < .001)。
  • 术后4年eGFR高于基线但无统计学显著性(P = .48)。
  • 术前eGFR<60组术后1个月显著升高(P < .001),4年时仍显著高于基线(P = .032)。
  • 术前eGFR>60组1、3、5年生存率分别为76%、54%、48%,eGFR<60组分别为71%、60%、48%(P = .92)。

临床怎么用

  • 术前肾功能不全不应作为LVAD植入的排除因素,术后肾功能可改善且长期生存不受影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated changes in estimated glomerular filtration rate (eGFR) after left ventricular assist device (LVAD) implant and the impact on long-term outcomes. METHODS: A retrospective analysis was conducted for 255 patients with LVADs, divided into 2 groups based on preimplant eGFR (<60 or >60 mL/min/1.73 m2) and into 6 grades (grade 1, >90 mL/min/1.73 m2 normal; grade 2, 60-89 mild dysfunction; grade 3, 45-59 moderate; grade 4, 30-44 moderate to severe; grade 5, 15-29 severe; or grade 6, <15 kidney failure). Changes in eGFR and the impact on long-term outcome and survival were analyzed. RESULTS: One-month postimplant eGFR of the total cohort increased from a baseline of 75.19 ± 34.35 to 118.97 ± 67.62 mL/min/1.73 m2(P < .001). eGRF 4 years postimplant was higher than baseline but not significantly (P = .48). Patients with a preimplant eGFR > 60 followed the same pattern as the entire cohort. The preimplant eGFR < 60 group had a significant increase at 1 month (P < .001), eGFR remained significantly higher than baseline 4 years postimplant (P = .032), and there was a sustained transition to improved distribution of renal function grade after LVAD implant. Post-LVAD implant survival at 1, 3, and 5 years for baseline eGFR > 60 was 76%, 54%, and 48% and for eGFR < 60 was 71%, 60%, and 48%, respectively (P = .92). CONCLUSIONS: Patients with a low preimplant eGFR derive benefit from LVAD therapy, with eGFR remaining elevated above preimplant levels. Preimplant renal dysfunction did not impact negatively on long-term morbidity and mortality.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Smail H, Hassan HA, Bowles C, et al. Impaired Baseline Renal Function May Not Influence Outcomes and Survival After Left Ventricular Assist Device Implantation. Ann Thorac Surg. 2020. PMID: 32698021. doi:10.1016/j.athoracsur.2020.05.127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。